Will be adding longer term biotech plays in a new page in the future for future runup trading. This will be filed later under 2013/2014 Catalysts.
ASTM: AASTROM Biosciences
Aastrom Biosciences, Inc. (Aastrom) is a development stage
company. The Company is focused on the development of cell therapies to repair
or regenerate damaged or diseased tissues. The Company is engaged in developing
patient-specific, expanded multicellular therapies for uses in the treatment of
severe, chronic ischemic cardiovascular diseases. The Company's
cell-manufacturing technology enables the manufacture of multicellular
therapies, expanded from an adult's own bone marrow and delivered directly to
damage tissues. The Company
released Phase IIb data from its RESTORE-CLI trial and launched its pivotal
Phase III REVIVE trial in CLI in February 2012.
2014 Catalysts:
- Phase 3 REVIVE-CLI clinical study of ixmyelocel-T in patients with critical limb ischemia; - Complete enrollment in 2014.. data??
- Phase 2b RENEW-DCM clinical study of ixmyelocel-T in patients with ischemic DCM; - Top line data ~ August 2014
There is a planned interim update after the first 300 patients are treated. Probably around mid to late 2013. It will be blinded to the company (and investors), but it should give us a sense of the overall AFS number. Similar to a cancer program, we generally know what to expect from the control group, so if the blinded AFS number is greater than what we are expecting for the control we can infer that the ixmy-T group is separating.
ReplyDeleteThanks for the information Jason.
ReplyDelete